Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics
10:36am, Wednesday, 29'th Apr 2026
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key met
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
09:30am, Wednesday, 29'th Apr 2026
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.75 per share a year ago.
Ionis reports first quarter 2026 financial results and highlights progress on key programs
07:00am, Wednesday, 29'th Apr 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the first quarter ended March 31, 2026.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Appl
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
07:00am, Tuesday, 21'st Apr 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexa
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $73,013.92 in Stock
05:14am, Monday, 20'th Apr 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Brian Birchler sold 973 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, April 16th. The stock was sold at an averag
B Lynne Parshall Sells 5,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
04:36am, Sunday, 19'th Apr 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director B Lynne Parshall sold 5,000 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was sold at an a
Kyle Jenne Sells 4,902 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
04:36am, Sunday, 19'th Apr 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Kyle Jenne sold 4,902 shares of the company's stock in a transaction dated Thursday, April 16th. The stock was sold at an average price
Ionis Pharmaceuticals (NASDAQ:IONS) and Akebia Therapeutics (NASDAQ:AKBA) Financial Analysis
04:11am, Saturday, 18'th Apr 2026
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both medical companies, but which is the superior business? We will compare the two
Ionis to hold first quarter 2026 financial results webcast
07:05am, Wednesday, 15'th Apr 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first qua
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Aberdeen Group plc
03:08am, Friday, 10'th Apr 2026
Aberdeen Group plc trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 67.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC
05:32am, Saturday, 04'th Apr 2026
SG Americas Securities LLC lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 548.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC.
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS
03:32am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 90.6% during the fourth quarter, according to the company in its most recent disclosure with
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
07:30am, Monday, 30'th Mar 2026
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patie
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?
12:31pm, Friday, 27'th Mar 2026
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
